A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

Pediatric Blood &Cancer, EarlyView.


from Cancer via ola Kala on Inoreader https://ift.tt/2rlYZaf
via IFTTT